Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4

Hyung S. Youn, Joo Y. Lee, Shin I. Saitoh, Kensuke Miyake, Daniel H. Hwang

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Toll-like receptors (TLRs), which are activated by invading microorganisms or endogenous molecules, evoke immune and inflammatory responses. TLR activation is closely linked to the development of many chronic inflammatory diseases including rheumatoid arthritis. Auranofin, an Au(I) compound, is a well-known and long-used anti-rheumatic drug. However, the mechanism as to how auranofin relieves the symptom of rheumatoid arthritis has not been fully clarified. Our results demonstrated that auranofin suppressed TLR4-mediated activation of transcription factors, NF-κB and IRF3, and expression of COX-2, a pro-inflammatory enzyme. This suppression was well correlated with the inhibitory effect of auranofin on the homodimerization of TLR4 induced by an agonist. Furthermore, auranofin inhibited NF-κB activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKβ, and p65. IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin. Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4. The results suggest that the suppression of TLR4 activity by auranofin may be the molecular mechanism through which auranofin exerts anti-rheumatic activity.

Original languageEnglish (US)
Pages (from-to)866-871
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume350
Issue number4
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Gold Compounds
Auranofin
Chemical activation
Toll-Like Receptors
Rheumatoid Arthritis
Antirheumatic Agents
Microorganisms
Chronic Disease
Transcription Factors
Down-Regulation

Keywords

  • Auranofin
  • COX-2
  • Dimerization
  • Gold
  • IKKβ
  • LPS
  • MyD88
  • NF-κB
  • Toll-like receptor
  • TRIF

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. / Youn, Hyung S.; Lee, Joo Y.; Saitoh, Shin I.; Miyake, Kensuke; Hwang, Daniel H.

In: Biochemical and Biophysical Research Communications, Vol. 350, No. 4, 01.12.2006, p. 866-871.

Research output: Contribution to journalArticle

Youn, Hyung S. ; Lee, Joo Y. ; Saitoh, Shin I. ; Miyake, Kensuke ; Hwang, Daniel H. / Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. In: Biochemical and Biophysical Research Communications. 2006 ; Vol. 350, No. 4. pp. 866-871.
@article{a12045fb24fc4134886e774ca7c83e08,
title = "Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4",
abstract = "Toll-like receptors (TLRs), which are activated by invading microorganisms or endogenous molecules, evoke immune and inflammatory responses. TLR activation is closely linked to the development of many chronic inflammatory diseases including rheumatoid arthritis. Auranofin, an Au(I) compound, is a well-known and long-used anti-rheumatic drug. However, the mechanism as to how auranofin relieves the symptom of rheumatoid arthritis has not been fully clarified. Our results demonstrated that auranofin suppressed TLR4-mediated activation of transcription factors, NF-κB and IRF3, and expression of COX-2, a pro-inflammatory enzyme. This suppression was well correlated with the inhibitory effect of auranofin on the homodimerization of TLR4 induced by an agonist. Furthermore, auranofin inhibited NF-κB activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKβ, and p65. IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin. Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4. The results suggest that the suppression of TLR4 activity by auranofin may be the molecular mechanism through which auranofin exerts anti-rheumatic activity.",
keywords = "Auranofin, COX-2, Dimerization, Gold, IKKβ, LPS, MyD88, NF-κB, Toll-like receptor, TRIF",
author = "Youn, {Hyung S.} and Lee, {Joo Y.} and Saitoh, {Shin I.} and Kensuke Miyake and Hwang, {Daniel H.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.bbrc.2006.09.097",
language = "English (US)",
volume = "350",
pages = "866--871",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4

AU - Youn, Hyung S.

AU - Lee, Joo Y.

AU - Saitoh, Shin I.

AU - Miyake, Kensuke

AU - Hwang, Daniel H.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Toll-like receptors (TLRs), which are activated by invading microorganisms or endogenous molecules, evoke immune and inflammatory responses. TLR activation is closely linked to the development of many chronic inflammatory diseases including rheumatoid arthritis. Auranofin, an Au(I) compound, is a well-known and long-used anti-rheumatic drug. However, the mechanism as to how auranofin relieves the symptom of rheumatoid arthritis has not been fully clarified. Our results demonstrated that auranofin suppressed TLR4-mediated activation of transcription factors, NF-κB and IRF3, and expression of COX-2, a pro-inflammatory enzyme. This suppression was well correlated with the inhibitory effect of auranofin on the homodimerization of TLR4 induced by an agonist. Furthermore, auranofin inhibited NF-κB activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKβ, and p65. IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin. Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4. The results suggest that the suppression of TLR4 activity by auranofin may be the molecular mechanism through which auranofin exerts anti-rheumatic activity.

AB - Toll-like receptors (TLRs), which are activated by invading microorganisms or endogenous molecules, evoke immune and inflammatory responses. TLR activation is closely linked to the development of many chronic inflammatory diseases including rheumatoid arthritis. Auranofin, an Au(I) compound, is a well-known and long-used anti-rheumatic drug. However, the mechanism as to how auranofin relieves the symptom of rheumatoid arthritis has not been fully clarified. Our results demonstrated that auranofin suppressed TLR4-mediated activation of transcription factors, NF-κB and IRF3, and expression of COX-2, a pro-inflammatory enzyme. This suppression was well correlated with the inhibitory effect of auranofin on the homodimerization of TLR4 induced by an agonist. Furthermore, auranofin inhibited NF-κB activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKβ, and p65. IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin. Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4. The results suggest that the suppression of TLR4 activity by auranofin may be the molecular mechanism through which auranofin exerts anti-rheumatic activity.

KW - Auranofin

KW - COX-2

KW - Dimerization

KW - Gold

KW - IKKβ

KW - LPS

KW - MyD88

KW - NF-κB

KW - Toll-like receptor

KW - TRIF

UR - http://www.scopus.com/inward/record.url?scp=33751011612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751011612&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.09.097

DO - 10.1016/j.bbrc.2006.09.097

M3 - Article

C2 - 17034761

AN - SCOPUS:33751011612

VL - 350

SP - 866

EP - 871

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -